Last Updated on Nov 3, 2021 by Ayushi Mishra

As part of its periodic review, NSE Indices Ltd modified the eligibility criteria and substituted stocks for various Nifty indices.

The Nifty Pharma Index went through a major reorganization. It used to constitute 10 companies. But now, 10 more companies got added to the list making it a total of 20 pharmaceutical companies.

If you focus on the returns, Nifty pharma recorded a growth of 25% over the past year. What can investors expect with the addition of 10 companies?

Well, with the increase of the companies in the Nifty Pharma index, the free float coverage of pharmaceutical companies will increase from 70% to 90%.

With this change, the various ETFs like Nippon India Nifty Pharma ETF will undergo rebalancing. This is so that they can closely track the revised Nifty Pharma Index.

These changes will come into effect from 30 September 2021. The 10 companies that would be added to the index are not yet finalised. One of the primary qualifying criteria for the selection of constituent companies in the Nifty Pharma Index is that a pharma business should be a part of the Nifty 500 at the time of the semi-annual review.

Ayushi Mishra
Inline Feedbacks
View all comments
55,00,000+ users trust Tickertape for Investment Analysis!
55,00,000+ users trust Tickertape for Investment Analysis!

The blog posts/articles on our platform are purely the author’s personal opinion and do not necessarily represent the views of Anchorage Technologies Private Limited (ATPL) or any of its associates. The content in these posts/articles is for informational and educational purposes only and should not be construed as professional financial advice. Should you need such advice, please consult a professional financial or tax advisor. The content on our platform may include opinions, analysis, or commentary, which are subject to change, without notice, based on market conditions or other factors. Further, the use of any third-party websites or services linked on the website is at the user's discretion and risk. ATPL is not responsible for the content, accuracy, or security of external sites. Investments in the securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. The examples and/or securities quoted (if any) are for illustration only and are not recommendatory. Any reliance you place on such information is strictly at your own risk. In no event will ATPL be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.

By accessing this platform and its blog section, you acknowledge and agree to the Terms and Conditions of this website, Privacy Policy and Disclaimer.